Download
00198_2024_Article_7208.pdf 2,15MB
WeightNameValue
1000 Titel
  • Real-world efficacy of a teriparatide biosimilar (RGB-10) compared with reference teriparatide on bone mineral density, trabecular bone score, and bone parameters assessed using quantitative ultrasound, 3D-SHAPER® and high-resolution peripheral computer tomography in postmenopausal women with osteoporosis and very high fracture risk
1000 Autor/in
  1. Hadji, Peyman |
  2. Kamali, Luka |
  3. Thomasius, Friederike |
  4. Horas, Konstantin |
  5. Kurth, Andreas |
  6. Bock, Nina |
1000 Verlag Springer London
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-08-02
1000 Erschienen in
1000 Quellenangabe
  • 35(12):2107-2116
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00198-024-07208-z |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11579072/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • A retrospective analysis comparing a teriparatide biosimilar (RGB-10) with reference teriparatide for osteoporosis treatment in postmenopausal women at high fracture risk found them to be therapeutically equivalent. Both provided significant improvements in lumber spine BMD, TBS, and other parameters of bone health, assessed using multiple diagnostic methods.!##!Purpose!#!To compare the therapeutic efficacy of a teriparatide biosimilar (RGB-10) with reference teriparatide for the treatment of osteoporosis in postmenopausal women at very high fracture risk.!##!Methods!#!A retrospective analysis of 25 postmenopausal female patients treated for osteoporosis with RGB-10 for 24 months and a matched cohort of 25 patients treated with reference teriparatide. The following outcomes were assessed at baseline, 12 and 24 months: bone mineral density (BMD) at the lumbar spine, femoral neck and total hip using dual-energy x-ray absorptiometry (DXA) and integral, trabecular and cortical volumetric and surface BMD using 3D-SHAPER!##!Results!#!No significant differences were observed between treatment groups in any of the measured parameters of BMD or bone health at baseline as well as in any timepoint when assessed using these various diagnostic methods. Both compounds provided equivalent significant improvements from baseline in measures of osteoporosis and fracture risk.!##!Conclusion!#!The results of the analysis demonstrate the therapeutic equivalence of the teriparatide biosimilar (RGB-10) to reference teriparatide for the treatment of osteoporosis in postmenopausal women at very high risk of fracture.
1000 Sacherschließung
lokal Absorptiometry, Photon/methods [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Osteoporotic Fractures/physiopathology [MeSH]
lokal Aged [MeSH]
lokal Osteoporosis, Postmenopausal/diagnostic imaging [MeSH]
lokal Osteoporosis, Postmenopausal/drug therapy [MeSH]
lokal Tomography, X-Ray Computed/methods [MeSH]
lokal Biosimilar Pharmaceuticals/pharmacology [MeSH]
lokal Cancellous Bone/diagnostic imaging [MeSH]
lokal Biosimilar Pharmaceuticals/administration
lokal Osteoporosis, Postmenopausal/physiopathology [MeSH]
lokal Original Article
lokal Bone Density Conservation Agents/therapeutic use [MeSH]
lokal Cancellous Bone/physiopathology [MeSH]
lokal Lumbar Vertebrae/physiopathology [MeSH]
lokal Biosimilar Pharmaceuticals/therapeutic use [MeSH]
lokal Imaging, Three-Dimensional/methods [MeSH]
lokal Lumbar Vertebrae/diagnostic imaging [MeSH]
lokal Biosimilar
lokal Fracture
lokal Teriparatide/pharmacology [MeSH]
lokal Female [MeSH]
lokal Bone Density Conservation Agents/administration
lokal Bone Density/drug effects [MeSH]
lokal Ultrasonography/methods [MeSH]
lokal Humans [MeSH]
lokal Treatment Outcome [MeSH]
lokal HRpQCT
lokal Retrospective Studies [MeSH]
lokal Femur Neck/physiopathology [MeSH]
lokal Middle Aged [MeSH]
lokal Osteoporosis
lokal Osteoporotic Fractures/prevention
lokal Bone Density Conservation Agents/pharmacology [MeSH]
lokal BMD
lokal Teriparatide/therapeutic use [MeSH]
lokal Teriparatide/administration
lokal Cancellous Bone/drug effects [MeSH]
lokal Osteoporotic Fractures/diagnostic imaging [MeSH]
lokal Teriparatide
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-4787-3151|https://frl.publisso.de/adhoc/uri/S2FtYWxpLCBMdWth|https://frl.publisso.de/adhoc/uri/VGhvbWFzaXVzLCBGcmllZGVyaWtl|https://frl.publisso.de/adhoc/uri/SG9yYXMsIEtvbnN0YW50aW4=|https://frl.publisso.de/adhoc/uri/S3VydGgsIEFuZHJlYXM=|https://frl.publisso.de/adhoc/uri/Qm9jaywgTmluYQ==
1000 Hinweis
  • DeepGreen-ID: 774659fa68da43c58f4d308f9560b439 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. STADA Arzneimittel AG |
  2. Philipps-Universität Marburg |
1000 Fördernummer
  1. -
  2. -
1000 Förderprogramm
  1. -
  2. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer STADA Arzneimittel AG |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer Philipps-Universität Marburg |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6520057.rdf
1000 Erstellt am 2025-07-05T22:19:16.065+0200
1000 Erstellt von 322
1000 beschreibt frl:6520057
1000 Zuletzt bearbeitet 2025-08-11T08:13:26.559+0200
1000 Objekt bearb. Mon Aug 11 08:13:26 CEST 2025
1000 Vgl. frl:6520057
1000 Oai Id
  1. oai:frl.publisso.de:frl:6520057 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source